MUNICH and ZUG, Switzerland, June 16, 2015 /PRNewswire/ --
Founding team places management in new hands
"2014 was a successful year for AmVac. Projects were advanced efficiently and in a targeted manner. Key milestones in preclinical and clinical product development were achieved. AmVac is well on track to develop from a research-focused start-up into a market-oriented company," says Marie Christine Kopkow, Chairwoman of AmVac AG. The company's founder, Melinda Karpati, adds: "We put in place the conditions for the handover with the successful transfer of operational management to Ali Pashazadeh in the first quarter of 2015, and are placing the future of AmVac in the hands of the next generation."
The founding team of Melinda Karpati and Marie Christine Kopkow have decided to resign from the Board of Directors of AmVac AG at the end of the current year of office. In doing so, they are paving the way for the election of three proven industry specialists at the Annual General Meeting on June 30, 2015.
The Board of Directors of AmVac AG decided, to propose the following new members for election to the Annual General Meeting:
Ali Pashazadeh
CEO of AmVac AG and founder of Treehill Partners. Prior to founding Treehill Partners, Ali Pashazadeh held senior positions at Blackstone, UBS and Goldman Sachs. He is a trained surgeon, holding an MBBS and BSc from St Mary's Hospital Medical School, London, as well as an MBA from London Business School.
Russell L. Gantt
Partner at Treehill Partners and Argo Navis BioPharm Advisors LLC. Russell L. Gantt has more than 30 years of experience in the pharmaceutical industry, including at Abbott Laboratories, Schering-Plough, Wyeth, Astra Merck and AstraZeneca. He holds a BSc from the University of Tennessee.
Michael Vogel
Managing Director of MV Portfoliomanagement GmbH, Chairman of the Board of Directors of iBlue AG, Chairman of the Advisory Board of Axiogenesis AG, Chairman of the Advisory Board of MagnaMedics GmbH and member of the Advisory Board of Curadis GmbH. Michael Vogel has considerable experience in the areas of private equity and venture capital and is a proven specialist in capital investments. He holds a diploma as a European Financial Consultant from the European Financial Academy (EFA).
The Board of Directors of AmVac AG would like to thank Melinda Karpati and Marie Christine Kopkow for their considerable personal commitment over the last ten years to the successful development of AmVac and for their willingness to continue to provide their vast experience to the company on a mandate basis.
AmVac - Tomorrow's Vaccines Today
AmVac AG is a biopharmaceutical company developing and marketing innovative vaccines. The life-science company was founded in 2005, is headquartered in Zug, Switzerland and has research laboratories in Germany and Italy, and a manufacturing operation in Hungary. Based on exclusive licenses from leading German scientific institutes of the Helmholtz- and Max-Planck societies and own acquired IP, AmVac has developed an innovative portfolio of seven vaccine candidates and three platform technologies - Lactobacillus, Sendai and Malp. The most advanced product of AmVac is Gynevac, based on the Lactobacillus platform. Previously already approved for selected indications in certain geographies, the product is currently being developed for the treatment of certain highly prevalent urogenital diseases on a broad international level. With its particularly favourable safety profile, Gynevac could, for the first time, offer an effective treatment or prevention of non-malignant prostate enlargement as well as inflammation and bacterial inflammation, virtually free of side effects. Lastly, AmVac is currently directing a part of its research program to a promising Ebola vaccine in its pipeline.
Contact
Dr. Ali Pashazadeh
Chief Executive Officer
T +41(0)417253230
pashazadeh@amvac.eu
Share this article